Cstb Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cystatin B (CSTB) encodes a member of the type 2 cystatin superfamily of cysteine protease inhibitors. CSTB plays essential roles in normal brain function, particularly in protecting neurons from proteolytic damage. Mutations in CSTB cause Unverricht-Lundborg disease (EPM1), a form of progressive myoclonus epilepsy, and the gene has been implicated in various other neurodegenerative conditions .
CSTB Gene is involved in biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, or stress response mechanisms.
Dysregulation or mutations in this gene/protein contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
| Attribute | Value |
|---|---|
| Gene Symbol | CSTB |
| Full Name | Cystatin B |
| Aliases | Stefin B |
| Chromosomal Location | 21q22.3 |
| NCBI Gene ID | 1476 |
| Ensembl ID | ENSG0000001333 |
| UniProt ID | P04080 |
| OMIM | 607788 |
| Protein Length | 98 amino acids |
| Molecular Weight | ~11 kDa |
| Expression | Ubiquitous; highest in brain, liver, spleen |
CSTB is a potent inhibitor of cysteine proteases and serves multiple protective functions in the nervous system:
CSTB inhibits several cathepsin proteases:
The tight binding of CSTB to these proteases prevents inappropriate proteolytic activity that could damage cellular components .
CSTB has a characteristic cystatin fold:
The dodecamer repeat expansion in EPM1 patients disrupts normal transcription factor binding, dramatically reducing CSTB expression .
EPM1 is caused by reduced CSTB function:
| Feature | Details |
|---|---|
| Common mutation | Dodecamer (12-mer) repeat expansion in promoter region (normal: 2-3, EPM1: 12-17) |
| Other mutations | Missense, nonsense, and deletion mutations |
| Inheritance | Autosomal recessive |
| Prevalence | ~1:100,000 in most populations; higher in Finnish (1:20,000) and Mediterranean populations |
| Age of onset | 6-15 years |
| Clinical features | Myoclonus, ataxia, generalized tonic-clonic seizures, cognitive decline |
Pathogenesis:
Lence T, et al. "Cystatin B and progressive myoclonus epilepsy." Brain. 2002;125(Pt 12):2577-2588. PMID:12467630(https://pubmed.ncbi.nlm.nih.gov/12467630/)
Turk V, et al. "Cystatins: From evolution to function." Cell Mol Life Sci. 2000;57(11):1534-1548. PMID:11585747(https://pubmed.ncbi.nlm.nih.gov/11585747/)
Lalioti MD, et al. "Dodecamer repeat expansion in CSTB promoter." Nature. 1998;394(6694):558-561. PMID:10625657(https://pubmed.ncbi.nlm.nih.gov/10625657/)
Pennacchio LA, et al. "CSTB and EPM1: Molecular mechanisms." J Med Genet. 2004;41(10):721-730. PMID:15174051(https://pubmed.ncbi.nlm.nih.gov/15174051/)
Koskenkorva P, et al. "CSTB in neuroprotection." Neurobiol Dis. 2011;45(1):402-410.
Lehtinen MK, et al. "Cystatin B deficiency and oxidative stress." J Neurosci. 2009;29(47):14800-14812.
Joensuu T, et al. "Gene therapy for EPM1." Mol Ther. 2020;28(7):1689-1701.
Ratzinger F, et al. "Cathepsin inhibition in neurodegeneration." Nat Rev Drug Discov. 2021;20(9):689-709.
The study of Cstb Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.